Now showing items 1-2 of 2

    • Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. 

      Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, Sridharan; Herndon, James Emmett II; Marcello, JE; ... (13 authors) (Br J Cancer, 2009-12-15)
      BACKGROUND: We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial. METHODS: A total of 59 patients, including 27 with glioblastoma (GBM) and 32 with grade ...
    • Molecular variants and mutations in medulloblastoma. 

      Gururangan, Sridharan; Schroeder, Kristin M (Pharmgenomics Pers Med, 2014)
      Medulloblastoma is the commonest malignant brain tumor in children. Treatment with surgery, irradiation, and chemotherapy has improved outcomes in recent years, but patients are frequently left with devastating neurocognitive ...